Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab
Description
The participating funds aim to conclude discount contracts pursuant to § 130a para. 8 SGB V for the active substance Adalimumab with all suitable pharmaceutical companies. The contract is concluded within the framework of the Open-House-Biologika procedure of the participating funds: individual negotiations on contract terms are not conducted, uniform conditions apply. The participating health insurance funds do not guarantee exclusivity to individual contractual partners. The contract term is a maximum of 24 months, beginning on 01.08.2025. The contract ends at the latest on 31.07.2027, regardless of the date of contract conclusion. All further information can be found in the participation and contract documents.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Miscellaneous medical devices and products – VE 473.05 105 Deckenversorgungseinheiten Medien
Universitätsklinikum HeidelbergGermanyMiscellaneous medical devices and productsInstallation services of medical equipmentDeadline in 29 daysPublished on Nov 19, 2026
Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption
BARMER Beschaffung und VergabeGermanyPharmaceutical productsDeadline in 619 daysPublished on Nov 19, 2026
Germany – Medical equipments, pharmaceuticals and personal care products – Absaugung, Invasive Blutdruckmessung und Regionalanästhesie
EK-UNICO GmbHGermanyMedical equipments, pharmaceuticals and personal care productsVenepuncture, blood sampling devicesAnaesthesia and resuscitationDeadline in 32 daysPublished on Nov 19, 2026
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Aflibercept, ausgenommen 114,3 mg/ml (ATC-Code: S01LA05).
AOK Niedersachsen. Die Gesundheitskasse.GermanyPharmaceutical productsDeadline in 707 daysPublished on Nov 19, 2026